More than three decades ago, Congress created the 340B program to help safety-net hospitals and clinics expand resources and care for underserved communities. By requiring pharmaceutical companies to ...

“When a program designed to deliver targeted assistance drives up system-wide costs, reform is no longer optional,” says health expert Sally Pipes. “It's necessary.” If a charity organization ...

Established under the Public Health Service Act in 1992, the 340B drug pricing program has a critical goal: improve access to medicines for low-income patients at qualifying hospitals and clinics.

The 340B Drug Pricing Program was created in 1992 to increase access to hospital outpatient medications for low‐income and uninsured patients by allowing covered entities that serve these patients to ...

A private business has helped supercharge a controversial federal drug program. Patients and insurers have been left with big bills. By Ellen Gabler Soon after being diagnosed with metastatic breast ...

It’s no surprise that chronic illness and affordability challenges can cause job loss, slow up wage gain and prevent work entirely. All Americans don’t share this burden equally, though. Minorities — ...

The program was meant to help hospitals provide for poor patients by offering drug savings. But critics say a Texas company has turned it into a big business, driving up costs for patients and ...

This past September, a sub-agency of the Department of Health and Human Services (HHS) threatened to kick a pharmaceutical company out of Medicare because the company, in line with federal law, ...

On July 31, the US Department of Health and Human Services’ (HHS) Health Resources and Services Administration (HRSA) announced the availability of a new pilot program altering how pharmaceutical ...

Four drug manufacturers have announced plans to offer discounted drug prices to safety net providers under the federal 340B program via rebates instead of upfront discounts, despite the federal ...

The 340B drug discount program has followed a familiar health policy trajectory. An intervention that was supposed to ease cost pressures, it instead is producing cascading unintended consequences ...